Cargando…

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review

Lung cancer is the leading cause of cancer related deaths. Among the two broad types of lung cancer, non-small cell lung cancer accounts for 85% of the cases. The study of the genetic alteration has facilitated the development of targeted therapeutic interventions. Some of the molecular alterations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puri, Megha, Gawri, Kunal, Dawar, Richa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461310/ https://www.ncbi.nlm.nih.gov/pubmed/37645429 http://dx.doi.org/10.3389/fonc.2023.1141876

Ejemplares similares

Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
por: Kareff, Samuel A., et al.
Publicado: (2023)

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

Therapeutic strategies in RET gene rearranged non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022)

The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer
por: Zhang, Longyao, et al.
Publicado: (2022)

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
por: Mu, Yuxin, et al.
Publicado: (2020)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
por: Liu, Surui, et al.
Publicado: (2022)

Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports
por: Michaux, Lionel, et al.
Publicado: (2023)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
por: Martin, Claudio, et al.
Publicado: (2022)

Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
por: Takeda, Hiroyuki, et al.
Publicado: (2021)

Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
por: Tanaka, Ichidai, et al.
Publicado: (2023)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients
por: Guan, Wen-Long, et al.
Publicado: (2020)

BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
por: Li, Ming, et al.
Publicado: (2021)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Non-small-cell lung cancer: how to manage BRAF-mutated disease
por: Guaitoli, Giorgia, et al.
Publicado: (2023)

Mathematical analysis identifies the optimal treatment strategy for epidermal growth factor receptor-mutated non-small cell lung cancer
por: Yu, Qian, et al.
Publicado: (2023)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

A Case of Success With Immunotherapy After Changing the Therapeutics Strategy in Non-small Cell Lung Cancer
por: Machado, Bárbara, et al.
Publicado: (2023)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
por: Ambrosini-Spaltro, Andrea, et al.
Publicado: (2023)

BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2014)

Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
por: Li, Junlong, et al.
Publicado: (2018)

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy
por: Banerjee, Natasha, et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
por: Cui, Jinfeng, et al.
Publicado: (2022)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
por: Pan, Yue, et al.
Publicado: (2021)

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
por: Lin, Quan, et al.
Publicado: (2019)

BRAF Inhibitors in Non-Small Cell Lung Cancer
por: Sforza, Vincenzo, et al.
Publicado: (2022)

Selection Strategies and Practical Application of BRAF V600E-Mutated Non–Small Cell Lung Carcinoma
por: Hwang, Inwoo, et al.
Publicado: (2022)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
por: Garon, Edward B., et al.
Publicado: (2023)

Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer
por: Duan, Yujuan, et al.
Publicado: (2022)

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
por: Bozorgmehr, Farastuk, et al.
Publicado: (2021)

Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
por: Zhao, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ck06q9ts0r9mr5e2j6rkk03ehv